Atıf Formatları
Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

M. Suicmez Et Al. , "Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway," ChemistrySelect , vol.9, no.20, 2024

Suicmez, M. Et Al. 2024. Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway. ChemistrySelect , vol.9, no.20 .

Suicmez, M., Namalir, G., Konuş, M., & Ozdil, H., (2024). Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway. ChemistrySelect , vol.9, no.20.

Suicmez, Menderes Et Al. "Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway," ChemistrySelect , vol.9, no.20, 2024

Suicmez, Menderes Et Al. "Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway." ChemistrySelect , vol.9, no.20, 2024

Suicmez, M. Et Al. (2024) . "Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway." ChemistrySelect , vol.9, no.20.

@article{article, author={Menderes Suicmez Et Al. }, title={Silencing of lncRNA UCA1 Reverses Doxorubicin Resistance of Breast Cancer Through Inhibiting PI3K/AKT/mTOR Signaling Pathway}, journal={ChemistrySelect}, year=2024}